COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,280 Articles (22,759 medRxiv, 8,521 bioRxiv)

Most recent first Previous |  Page 800: Articles 7991-8000  | Next

Socioeconomic inequality in SARS-CoV-2 testing and COVID-19 outcomes in UK Biobank over the first year of the pandemic: can inequalities be explained byselection bias?
Carter, A. R., Clayton, G. L., Borges, M. C., Howe, L. D., Hughes, R. A., Davey Smith, G., Lawlor, D. A., Tilling, K., Griffith, G. J.
10.1101/2022.05.05.22274721 — Posted: 2022-05-05
UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern
Wang, C. Y., Hwang, K.-P., Kuo, H.-K., Kuo, B.-S., Liu, H., Hou, K.-L., Tsai, W.-Y., Chiu, H.-C., Ho, Y.-H., Cheng, J., Wang, M.-S., Yang, Y.-T., Chang, P.-Y., Shen, Y.-H., Peng, W.-J.
10.1101/2022.04.11.22272364 — Posted: 2022-05-05
Longitudinal analyses of depression and anxiety highlight greater prevalence during COVID-19 lockdowns in the Dutch general population and a continuing increase in suicidal ideation in young adults
Ori, A. P., Wieling, M., Lifelines Corona Research Initiative, , van Loo, H. M.
10.1101/2022.05.02.22273554 — Posted: 2022-05-05
Adsorption of Pulmonary and Exogeneous Surfactants on SARS-CoV-2 Spike Protein
Santo, K. P., Neimark, A. V.
10.1101/2022.05.04.490631 — Posted: 2022-05-04
SARS-CoV-2 variants do not evolve to promote further escape from MHC-I recognition
Moriyama, M., Lucas, C., Monteiro, V. S., Iwasaki, A.
10.1101/2022.05.04.490614 — Posted: 2022-05-04
Accident and emergency (AE) attendance in England following infection with SARS-CoV-2 Omicron or Delta
Grint, D. J., Wing, K., Gibbs, H. P., Evans, S. J., Williamson, E. J., Bhaskaran, K., McDonald, H. I., Walker, A. J., Evans, D., Hickman, G., Mathur, R., Schultze, A., Rentsch, C. T., Tazare, J., Douglas, I. J., Curtis, H. J., Morton, C. E., Bacon, S. C., Davy, S., MacKenna, B., Inglesby, P., Croker, R., Parry, J., Hester, F., Harper, S., DeVito, N. J., Hulme, W. J., Bates, C., Cockburn, J., Mehrkar, A., Goldacre, B., Eggo, R. M., Tomlinson, L.
10.1101/2022.05.03.22274602 — Posted: 2022-05-03
Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies
Yamasoba, D., Kosugi, Y., Kimura, I., Fujita, S., Uriu, K., Ito, J., Sato, K., The Genotype to Phenotype Japan (G2P-Japan) Consortium
10.1101/2022.05.03.490409 — Posted: 2022-05-03
Spatiotemporal landscape of SARS-CoV-2 pulmonary infection reveals Slamf9+Spp1+ macrophages promoting viral clearance and inflammation resolution
Cong, B., Dong, X., Yang, Z., Yu, P., Chai, Y., Liu, J., Zhang, M., Zang, Y., Kang, J., Feng, Y., Liu, Y., Feng, W., Deng, W., Li, F., Yu, Q., Gu, Y., Li, Z., Liu, S., Xu, X., Zhong, N., Ren, X., Qin, C., Liu, L., Wang, J., Cao, X.
10.1101/2022.05.03.490381 — Posted: 2022-05-03
Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine
Su, D., Li, X., Huang, X., He, C., Zeng, C., Wang, Q., Mu, Z., Qin, W., Ambrosino, D., Siber, G., Clemens, R., Liang, J. G., Liang, P., Jackson, N., Xu, R.
10.1101/2022.05.03.490428 — Posted: 2022-05-03
Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients with Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study
Shehab, M., Alrashed, F., Alfadhli, A., Alsayegh, A., Aldallal, U., Cherian, P., Alkhairi, I., Thanaraj, T. A., Channanath, A., Dashti, A. A., Albanaw, A., Ali, H., Abu-Farha, M., Abubaker, J. T., Al-Mulla, F.
10.1101/2022.05.03.22274608 — Posted: 2022-05-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).